Peptides DB

Research-centric peptide and protocol reference hub

Adalank (N-Acetyl Selank Amidate) vs KPV

Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team

Adalank (N-Acetyl Selank Amidate): Research use — not FDA-approvedKPV: Research use — not FDA-approved

A data-driven comparison of Adalank (N-Acetyl Selank Amidate) and KPV (also searched as KPV vs Adalank (N-Acetyl Selank Amidate)) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.

Verdict

Adalank (N-Acetyl Selank Amidate) centers on neuro, while KPV leans toward healing. On indexed research, KPV is ahead (Adalank (N-Acetyl Selank Amidate): 0 studies, Emerging; KPV: 6, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.

Key takeaways

  • Adalank (N-Acetyl Selank Amidate) is strongest for neuro; KPV for healing.
  • Evidence: Adalank (N-Acetyl Selank Amidate) Emerging (0 studies) vs KPV Human evidence (6).
  • Both are research-use compounds — not FDA-approved.

Effect profiles, overlaid

HealingMuscleMetabolicNeuroSleepInflammationSkin
Adalank (N-Acetyl Selank Amidate)KPV

At a glance

N-Acetyl Selank Amidate | Enhanced Tuftsin Analog

Strongest: NeuroStudies: 0Level: Emerging
KPVHuman evidence

Anti-Inflammatory Tripeptide | Alpha-MSH Fragment

Strongest: HealingStudies: 6Level: Emerging

Adalank (N-Acetyl Selank Amidate) vs KPV: side-by-side

MetricAdalank (N-Acetyl Selank Amidate)KPV
ClassCognitiveImmune
Regulatory statusResearch use onlyResearch use only
Evidence gradeEmergingHuman evidence
Studies indexed06
Research levelEmergingEmerging
Strongest effectNeuro & moodHealing & recovery
Healing & recovery0.04.0
Muscle & body comp0.00.0
Metabolic & appetite0.00.0
Neuro & mood4.00.0
Sleep & circadian0.00.0
Inflammation & immune0.04.0
Skin & aesthetics0.02.0

▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).

Mechanism & pharmacokinetics

PropertyAdalank (N-Acetyl Selank Amidate)KPV
MechanismAnxiolytic heptapeptide (Tuftsin analog)
RouteIntranasal / subcutaneous (research use)

Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.

What is Adalank (N-Acetyl Selank Amidate)?

Adalank (N-Acetyl Selank Amidate) is a modified analog of the Russian heptapeptide Selank, designed for enhanced metabolic stability and investigated for anxiolytic and nootropic effects.

Full Adalank (N-Acetyl Selank Amidate) profile, mechanism & studies →

What is KPV?

### KPV Summary KPV is a tripeptide composed of lysine, proline, and valine, which has garnered interest in research for its potential roles in modulating immune responses and promoting wound healing. Its implications in various therapeutic contexts, particularly in inflammatory conditions, are currently being explored.

Full KPV profile, mechanism & studies →

Which is better for your goal?

GoalBetter fitWhy
HealingKPV4.0/5 effect signal
NeuroAdalank (N-Acetyl Selank Amidate)4.0/5 effect signal
InflammationKPV4.0/5 effect signal
SkinKPV2.0/5 effect signal

Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.

Can you stack Adalank (N-Acetyl Selank Amidate) and KPV?

People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.

Adalank (N-Acetyl Selank Amidate) vs KPV: side effects

Adalank (N-Acetyl Selank Amidate)

No community-reported effects logged yet.

KPV

No community-reported effects logged yet.

Anonymous community reports (count = number of reports), not clinical incidence rates.

What the research says

Adalank (N-Acetyl Selank Amidate) has 0 approved studies indexed (Emerging), and KPV has 6 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.

Frequently asked questions

Is Adalank (N-Acetyl Selank Amidate) or KPV better?

It depends on your goal. Adalank (N-Acetyl Selank Amidate) is strongest for neuro; KPV for healing. KPV has more indexed studies (6). See the goal-by-goal breakdown above.

Which has more research, Adalank (N-Acetyl Selank Amidate) or KPV?

Adalank (N-Acetyl Selank Amidate) has 0 approved studies indexed (Emerging); KPV has 6 (Human evidence). Higher counts mean more to read, not proven superiority.

Can you stack Adalank (N-Acetyl Selank Amidate) and KPV?

Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.

What are the side effects of Adalank (N-Acetyl Selank Amidate) vs KPV?

Adalank (N-Acetyl Selank Amidate): no community-reported effects logged yet. KPV: none logged yet. These are anonymous reports, not incidence rates — see each profile.

Is Adalank (N-Acetyl Selank Amidate) or KPV FDA-approved?

Adalank (N-Acetyl Selank Amidate) is a research-use compound and is not FDA-approved. KPV is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.

Is KPV better than Adalank (N-Acetyl Selank Amidate)?

For healing, KPV has the edge; for neuro, Adalank (N-Acetyl Selank Amidate) does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.

Comparing related peptides

Regulatory & legal status

Adalank (N-Acetyl Selank Amidate) and KPV are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.